ANNX VS OPTN Stock Comparison

Performance

ANNX
10/100

ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

OPTN
10/100

OPTN returned -45.33% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.

Sentiment

ANNX
72/100

ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.

OPTN
73/100

OPTN had a bullish sentiment score of 72.50% across Twitter and StockTwits over the last 12 months. It had an average of 3.02 posts, 2.33 comments, and 8.84 likes per day.

Technicals

ANNX
64/100

ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

OPTN
71/100

OPTN receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

ANNX
10/100

ANNX has missed earnings 7 times in the last 20 quarters.

OPTN
10/100

OPTN has missed earnings 9 times in the last 20 quarters.

Profit

ANNX
10/100

Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.

OPTN
10/100

Out of the last 20 quarters, OPTN has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ANNX
49/100

ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

OPTN
45/100

OPTN has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Analyst Price Targets

ANNX

"Analyst Price Targets" not found for ANNX

OPTN
81/100

4 analysts offer 12-month price targets for OPTN. Together, they have an average target of 4.5, the most optimistic target put OPTN at 5 within 12-months and the most pessimistic has OPTN at 4.

All score calculations are broken down here to help you make more informed investing decisions

Annexon, Inc. Common Stock Summary

Nasdaq / ANNX

Healthcare

Biotechnology

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

OptiNose, Inc. Common Stock Summary

Nasdaq / OPTN

Healthcare

Drug Manufacturers - Specialty & Generic

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Power up your portfolio